New cancer drug saruparib enters early human testing

NCT ID NCT06899061

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new drug, saruparib, in 41 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, how it interacts with other common medications, and how well different pill versions work. This study is not designed to cure cancer but to gather important information for future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Saruparib (a drug taken by mouth)
What this could lead to: If successful, this trial could help determine the right dose of saruparib and how it interacts with other drugs, potentially leading to better treatment options for advanced solid tumors.
What could go wrong: This is a very early (Phase 1) study with only 41 participants. It primarily looks at drug levels and safety, not whether the drug shrinks tumors. Many early-stage drugs do not advance to become treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID MALIGNANCIES

Contacts and locations

Locations

Research Site

Sofia, 1618, Bulgaria
Research Site

Chisinau, MD-2025, Moldova
Research Site

Bucharest, 022338, Romania
Research Site

Cluj-Napoca, 400015, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.